Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies

1 Aug 2020

Abstract excerpt

As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32768882
DOI: 10.1016/j.biopha.2020.110559

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic AntibodiesPMID 32768882Read ↗

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinSemantic proximity Read ↗

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinSemantic proximity Read ↗

SARS-CoV-2 spike S2-specific neutralizing antibodiesSemantic proximity Read ↗

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.Semantic proximity Read ↗

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read ↗

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read ↗

Structural Insights into the SARS-CoV-2 Spike Protein and Its Implications for Antibody Resistance.Semantic proximity Read ↗

A Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2Semantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

Broadly neutralizing antibodies against COVID-19Semantic proximity Read ↗

Synthetic Monoclonal Antibody Designed for Novel SARS-nCoV-2 Spike-S1 Protein Antigenic Targeted Epitope of Receptor Binding Domain Inhibit to Prevent Viral EntrySemantic proximity Read ↗

Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.